SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Ziopharm Oncology Inc – ‘8-K’ for 12/29/10

On:  Wednesday, 1/5/11, at 1:33pm ET   ·   For:  12/29/10   ·   Accession #:  1144204-11-721   ·   File #:  1-33038

Previous ‘8-K’:  ‘8-K’ on / for 12/28/10   ·   Next:  ‘8-K’ on 1/12/11 for 1/6/11   ·   Latest:  ‘8-K’ on 2/22/24 for 2/15/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 1/05/11  Ziopharm Oncology Inc             8-K:8,9    12/29/10    2:60K                                    Vintage/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     21K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     17K 


8-K   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K


 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 29, 2010



ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
   
84-1475642
(State or Other Jurisdiction
of Incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)

1180 Avenue of the Americas
19th Floor
New York, NY
 
10036
(Address of Principal Executive Offices)
 
(Zip Code)

(646) 214-0700
(Registrant’s telephone number, including area code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)


 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
 
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
 
 
¨
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
 
 
 

 

Item 8.01          Other Events.
 
On December 29, 2010, the Company issued a press release announcing that the first patient has been dosed in a Phase I, single arm, dose escalation study at the Indiana University Cancer Center of intravenous (IV) palifosfamide (ZIO-201) in combination with etoposide (VP-16) and cisplatin/carboplatin (platinum) in the treatment of small cell lung cancer (SCLC) and other cancers.  A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
 
Item 9.01          Financial Statements and Exhibits.
 
    (d)
Exhibits
   
       
 
Exhibit No.
 
Description
 
99.1
 
Press Release dated December 29, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
ZIOPHARM Oncology, Inc.
   
 
By:
 
   
Title: President, Chief Operating Officer and Chief
Financial Officer
 
 
 

 

INDEX OF EXHIBITS
 
Exhibit No.
 
Description
     
99.1
 
Press Release dated December 29, 2010

 
 

 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:1/5/11None on these Dates
For Period End:12/29/10
 List all Filings 
Top
Filing Submission 0001144204-11-000721   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 7:08:27.2am ET